electroCore (NASDAQ: ECOR) is one of 47 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare electroCore to related businesses based on the strength of its earnings, dividends, valuation, institutional ownership, analyst recommendations, risk and profitability.
Institutional & Insider Ownership
14.5% of electroCore shares are held by institutional investors. Comparatively, 48.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 16.3% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares electroCore and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares electroCore and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|electroCore Competitors||$1.19 billion||$88.57 million||18.03|
electroCore’s rivals have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and price targets for electroCore and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
electroCore presently has a consensus price target of $20.67, indicating a potential upside of 236.04%. As a group, “Electromedical equipment” companies have a potential upside of 22.92%. Given electroCore’s stronger consensus rating and higher possible upside, analysts plainly believe electroCore is more favorable than its rivals.
electroCore Company Profile
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.